108 related articles for article (PubMed ID: 648158)
1. Circulating levels of norethindrone in women with a single silastic implant.
Goyal V; Joshi UM; Naik VK
Contraception; 1978 Apr; 17(4):375-82. PubMed ID: 648158
[TBL] [Abstract][Full Text] [Related]
2. Long-term contraception by a single silastic implant-D containing norethindrone acetate in women: a clinical evaluation.
Takkar D; Anandalaxmi PN; Chandra VL; Bhatnagar S; Yadav HS; Laumas KR; Hingorani V; Krishna U; Mandleker A; Purandare VN; Goel V; Adatia A; Virker KD
Contraception; 1978 Apr; 17(4):341-54. PubMed ID: 648156
[TBL] [Abstract][Full Text] [Related]
3. Subdermal norethindrone pellets -- a method for contraception?
Odlind V; Moo-Young AJ; Gupta GN; Weiner E; Johansson ED
Contraception; 1979 Jun; 19(6):639-48. PubMed ID: 487813
[TBL] [Abstract][Full Text] [Related]
4. Control of fertility with oral medication.
Diddle AW; Watts GF; Gardner WH; Williamson PJ
West J Surg Obstet Gynecol; 1964; 72():222-9. PubMed ID: 12305556
[TBL] [Abstract][Full Text] [Related]
5. Long-term contraception by steroid releasing implants. VI. Serum concentrations of norethindrone in women bearing a single silastic implant releasing norethindrone acetate.
Hillier SG; Jha P; Griffiths K; Laumas KR
Contraception; 1977 Apr; 15(4):473-88. PubMed ID: 880821
[TBL] [Abstract][Full Text] [Related]
6. Effect of norethindrone acetate released from a single silastic implant on serum FSH, LH, progesterone and estradiol-17beta of women during first eight months of treatment.
Rahman SA; Jha P; Laumas V; Jain AK; Dileepkumar ; Takkar D; Hingorani V; Laumas KR
Contraception; 1977 Nov; 16(5):487-97. PubMed ID: 590011
[TBL] [Abstract][Full Text] [Related]
7. Norethisterone contraceptive microspheres.
Rivera R; Alvarado G; Flores C; Aldaba S; Hernandez A
J Steroid Biochem; 1987; 27(4-6):1003-7. PubMed ID: 3695501
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous bioabsorbable pellets of norethindrone for contraception in women: Phase I. Clinical study.
Gupta GN; Saxena BB; Landesman R; Ledger WJ
Fertil Steril; 1984 May; 41(5):726-31. PubMed ID: 6714449
[TBL] [Abstract][Full Text] [Related]
9. Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: noresthisterone oenanthate and medroxyprogesterone acetate. 2. Bleeding patterns and side effects.
Contraception; 1978 May; 17(5):395-406. PubMed ID: 657807
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of norethindrone acetate in women after the insertion of a single subdermal implant releasing norethindrone acetate.
Singh H; Uniyal JP; Jha P; Takker D; Murguesan K; Hingorani V; Laumas KR
Acta Endocrinol (Copenh); 1982 Feb; 99(2):302-8. PubMed ID: 7058686
[TBL] [Abstract][Full Text] [Related]
11. Long-term contraception by steroid-releasing implants. II. A preliminary report on long-term contraception by a single silastic implant containing norethindrone acetate (ENTA) in women.
Bhatnagar S; Srivastava UK; Takkar D; Chandra VL; Hingorani V; Laumas KR
Contraception; 1975 May; 11(5):505-21. PubMed ID: 1139938
[TBL] [Abstract][Full Text] [Related]
12. Reduction of the oral contraceptive estrogen burden by alternate day estrogen administration.
Segre EJ; Henzl MR; Giner J; Scheel C; Bessler S
Contraception; 1975 Aug; 12(2):155-74. PubMed ID: 1139955
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of injectable biodegradable contraceptive system.
Beck LR; Ramos RA; Flowers CE; Lopez GZ; Lewis DH; Cowsar DR
Am J Obstet Gynecol; 1981 Aug; 140(7):799-806. PubMed ID: 7020421
[TBL] [Abstract][Full Text] [Related]
14. Plasma levels of norethisterone in women with subcutaneous implants of norethisterone acetate.
Joshi JV; Naik VK; Joshi UM
Indian J Med Res; 1979 Oct; 70():625-31. PubMed ID: 541006
[TBL] [Abstract][Full Text] [Related]
15. Contraceptive efficacy, pharmacokinetics, and safety of Annuelle biodegradable norethindrone pellet implants.
Raymond EG; Singh M; Archer DF; Saxena BB; Baker J; Cole D
Fertil Steril; 1996 Dec; 66(6):954-61. PubMed ID: 8941061
[TBL] [Abstract][Full Text] [Related]
16. Long-term study of oral contraception with norethindrone 2 mg. and mestranol 0.1 mg.
Hutcherson WP; Schwartz HA; Weathers W
Fertil Steril; 1966; 17(1):59-67. PubMed ID: 5901012
[TBL] [Abstract][Full Text] [Related]
17. Serum norethindrone (NET) concentrations following intramuscular NET enanthate injection. Effect upon serum LH, FSH, estradiol and progesterone.
Goebelsmann U; Stanczyk FZ; Brenner PF; Goebelsmann AE; Gentzschein EK; Mishell DR
Contraception; 1979 Mar; 19(3):283-313. PubMed ID: 572279
[TBL] [Abstract][Full Text] [Related]
18. A clinical trial of norethisterone oenanthate (Norigest) injected every two months.
Howard G; Blair M; Chen JK; Fotherby K; Muggeridge J; Elder MG; Bye PG
Contraception; 1982 Apr; 25(4):333-40. PubMed ID: 7049569
[TBL] [Abstract][Full Text] [Related]
19. Use of Anovlar in gynaecological disorders and contraception.
Shahani SM; Chiklikar A
J Obstet Gynaecol India; 1968 Apr; 18(2):592-7. PubMed ID: 12331827
[TBL] [Abstract][Full Text] [Related]
20. Accumulation of norethindrone and individual metabolites in human plasma during short- and long-term administration of a contraceptive dosage.
Braselton WE; Lin TJ; Ellegood JO; Mills TM; Mahesh VB
Am J Obstet Gynecol; 1979 Jan; 133(2):154-60. PubMed ID: 369375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
